Akari Therapeutics, Plc (AKTX)

Akari Therapeutics, Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	22	16	28	71	63	37
Market Cap Growth	-47.01%	-43.38%	-60.94%	13.96%	70.41%	53.49%
Enterprise Value	20	12	15	62	49	31
PE Ratio	-	-1.58	-1.57	-4.10	-3.67	-2.18
PB Ratio	-4.16	-68.96	15.57	12.85	6.68	4838.79
P/FCF Ratio	-	-0.96	-1.30	-3.79	-3.70	-2.85
P/OCF Ratio	-	-0.96	-1.30	-3.79	-3.70	-2.85
EV/EBITDA Ratio	-	-1.19	-0.82	-3.56	-2.85	-1.84
EV/EBIT Ratio	-	-1.19	-0.82	-3.56	-2.84	-1.84
EV/FCF Ratio	-	-0.73	-0.68	-3.29	-2.87	-2.40
Quick Ratio	0.21	0.84	1.10	1.54	2.69	0.89
Current Ratio	0.44	0.95	1.15	1.91	2.79	1.00
Return on Equity (ROE)	-	-1281.40%	-483.20%	-310.60%	-352.30%	-2169.60%
Return on Assets (ROA)	-	-110.10%	-139.30%	-178.50%	-129.60%	-216.60%
Return on Capital (ROIC)	-	7338.86%	-1289.11%	-309.91%	-191.61%	-223257.70%
Earnings Yield	-63.38%	-63.64%	-24.41%	-27.26%	-45.82%
FCF Yield	-104.06%	-77.11%	-26.40%	-27.06%	-35.14%
Buyback Yield / Dilution	-115.48%	-56.79%	-45.46%	-35.87%	-72.53%	-18.87%
Total Shareholder Return	-115.48%	-56.79%	-45.46%	-35.87%	-72.53%	-18.87%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).